-- (Moderated) The NEW Official Alizyme Thread: The Next Phase --

Its not as if that was a one off post either. FWIW I am a holder of OXB too!


QAZWSX123 - 9 Mar'04 - 16:23 - 12 of 14


I hope you will find these comments about Oxford Biomedica helpful, as follows:

1) Resources spread too thinly over too many high risk early stage expensive products.
2) Lead product Trovax not on the market until 2010/11 at the earliest, if at all.
3) Failed gene discovery division.
4) CEO prone to over egging in interviews.
5) Failed to make early single territory licensing deal for Trovax, suggested by CEO a few years ago.
6) Failed to link-up with British Biotech, suggested by CEO in early 2003.
7) Consistently overrun on announcement of trial results.
8) Roche already have an anti-cancer drug "Xeloda" approved by the FDA in 1998, and others have similar drugs in trials, e.g. Antigenics; Genetech "Avastin" for colon cancer; and ImClone Systems "Erbitux" for colon cancer.
9) Further dilutive share issues probably needed in 2006 and 2008. (I also think there will be one in late 2004).

When you consider the facts, it makes little sense to put money into OXB, especially when there are better and safer opportunities elsewhere imo.